You might have read our latest blog post on Chris Elliott Fund’s President and CEO’s journey across the country advocating for brain cancer and brain tumor patients and caregivers.
Interested in enrolling in a clinical trial for your brain tumor (regarding the trials listed below or any other trial across the country)? Contact us today. We regularly assist patients in identifying clinical trials appropriate for their situation.
Below you will find links and information to the most recent offerings at the University of California, San Diego and Tocagen.
University of California, San Diego Neurology Oncology Program Clinical Trials
Offerings for Candidates:
- Newly Diagnosed
- Nontherapeutic Trials.
In total, the University of California, San Diego is enrolling in 19 clinical trials for a range of candidates. Dr. Santosh Kesari, a member of the Chris Elliott Fund’s Medical Advisory Board, is a doctor we regularly refer patients to in California. He is pictured right with Chris Elliott Fund’s Board Chair and Vice President Tamara DePorter at the 2012 Brains Matter Patient & Caregiver Conference and Awareness Day hosted by the Chris Elliott Fund.
To see the full list of clinical trial offerings at UCSD: download it here. Something you are interested in? Please don’t hesitate to give the Chris Elliott Fund a phone call or email.
Tocagen: Clinical Trials for the Toca 511 & Toca FC Immunotherapy Research
Also in our recent blog post about CEF President and CEO’s advocacy across the country, we mentioned that Dellann met with Product Manager & Head of Business development Nick Boyle, as well as Dan Pertschuk, MD , Vice President of Clinical Development at Tocagen. Tocagen is an innovative bio-pharmaceutical company finding treatment for cancer using selective immunotherapy products.
They are presently seeking a larger population to enroll in their clinical trials in locations across the country. We at the Chris Elliott Fund are excited to help grow their study sample. Tocagen is conducting investigational clinical trials of Toca 511 and Toca FC at select neuro-oncology centers in the US.
A patient may qualify for Toca 511 & Toca FC if the patient:
- Has a recurrent high grade glioma (Grade 3 or Grade 4)
- Has had prior surgery, radiation and chemotherapy
- Is at least 18 years of age
They are currently enrolling at centers in Los Angeles, CA, University of San Francisco, CA, San Diego, CA, Cleveland, OH, Edison, NJ, Detroid, MI, and Columbus, OH. The Chris Elliott Fund is currently working with Tocagen in opening up a trial in Seattle, WA. We are also actively working with Tocagen to secure more clinical trial offerings in even more cities across the country.